Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLX001
- Development stage
- Preclinical
- Lead developer
- ValiRx
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
01
Overview
CLX001 is a peptide-based antineoplastic agent formulated in nanoparticles. It is being developed by Cytolytix, a subsidiary of ValiRx, and was originally licensed from King's College London. The drug acts as a cell death stimulant and modulates cell membrane permeability, enhancing the ability to disrupt cancer cell membranes. Its primary indication has been for triple negative breast cancer; however, it has also been investigated for other solid tumors. As of the latest updates, development appears to have been discontinued at the preclinical stage[2][4].
Beyond the preview
Go deeper on CLX001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLX001.